Sobi to acquire Dova Pharmaceuticals creating a global growth platform in haematology
Swedish Orphan Biovitrum AB (publ) (Sobi?) (STO:SOBI) today announced a definitive agreement to acquire Dova Pharmaceuticals, Inc. (NASDAQ:DOVA) by means of a tender offer. The consideration consists of an upfront payment of USD 27.50 per share in cash and, one non-tradeable Contingent Value Right (CVR). The CVR entitles Dova shareholders to an additional USD 1.50 per share upon approval of Doptelet? for use in Chemotherapy-Induced Thrombocytopenia (CIT) by the US Food and Drug Administration (FDA). The upfront cash component of the offer represents a premium of 36 per cent based on Dova?s most recent closing price of USD 20.19. The transaction is valued at up to USD 915 million (approximately SEK 9.0 billion) on a fully diluted basis.
- The acquisition of Dova provides Sobi with Doptelet (avatrombopag), a differentiated on-market product in Chronic Immune Thrombocytopenia (ITP), a well established and growing market, for Chronic Liver Disease (CLD) and an ongoing phase 3 trial in Chemotherapy Induced Thrombocytopenia (CIT)
- The acquisition of Dova will broaden the scope of Sobi?s product portfolio into haematology and enhance Sobi?s commercial presence in the United States
- Doptelet will further diversify Sobi?s revenue base adding a new growth driver
- Sobi will leverage its expertise and existing infrastructure in haematology to grow Doptelet across its indications by expanding patient access outside the US.
Paula Treutiger, Head of Communication & Investor Relations |
+ 46 733?666 599 |
paula.treutiger@sobi.com |
Linda Holmstr?m, Corporate Communication & Investor Relations |
+ 46 708?734 095 |
linda.holmstrom@sobi.com |